TimesSquare Capital Management LLC Has $113.15 Million Position in IDEXX Laboratories, Inc. $IDXX

TimesSquare Capital Management LLC reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 167,251 shares of the company’s stock after selling 25,687 shares during the period. IDEXX Laboratories comprises 1.7% of TimesSquare Capital Management LLC’s portfolio, making the stock its 6th biggest position. TimesSquare Capital Management LLC’s holdings in IDEXX Laboratories were worth $113,150,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. EverSource Wealth Advisors LLC lifted its stake in shares of IDEXX Laboratories by 2.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after acquiring an additional 15 shares during the last quarter. CWA Asset Management Group LLC lifted its stake in shares of IDEXX Laboratories by 3.5% during the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock worth $344,000 after acquiring an additional 17 shares during the last quarter. Stratos Wealth Partners LTD. lifted its stake in shares of IDEXX Laboratories by 1.7% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock worth $683,000 after acquiring an additional 18 shares during the last quarter. Cary Street Partners Investment Advisory LLC lifted its stake in shares of IDEXX Laboratories by 11.5% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock worth $111,000 after acquiring an additional 18 shares during the last quarter. Finally, Rockland Trust Co. lifted its stake in shares of IDEXX Laboratories by 4.4% during the 4th quarter. Rockland Trust Co. now owns 425 shares of the company’s stock worth $288,000 after acquiring an additional 18 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the transaction, the chief executive officer directly owned 83,606 shares in the company, valued at $54,975,125.30. This trade represents a 21.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Nimrata Hunt sold 2,693 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the transaction, the executive vice president owned 19,899 shares in the company, valued at $13,163,984.46. The trade was a 11.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 27,777 shares of company stock worth $18,235,113 over the last 90 days. 0.79% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of research analyst reports. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Citigroup initiated coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Barclays decreased their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Finally, Piper Sandler reduced their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Trading Up 3.2%

IDXX opened at $545.79 on Tuesday. The stock’s fifty day moving average is $570.62 and its two-hundred day moving average is $644.92. The company has a market capitalization of $43.05 billion, a P/E ratio of 40.19, a PEG ratio of 3.07 and a beta of 1.58. IDEXX Laboratories, Inc. has a 52 week low of $496.61 and a 52 week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.